Respiratory Syncytial Virus (RSV) is a widespread infection that can affect anyone. But the virus poses a heightened threat to infants, young children, seniors and those with compromised immune systems. The virus tends to circulate more frequently during fall and winter. Gaining awareness of the virus’ symptoms, risk factors and available vaccines can help safeguard vulnerable individuals.
What is RSV?
RSV is a highly infectious virus that impacts the respiratory system, particularly the lungs and airways. While most cases result in mild symptoms resembling a cold, some individuals may develop more severe respiratory illnesses, such as bronchiolitis and pneumonia. These more serious cases often occur in infants and the elderly. The virus spreads through droplets when an infected person coughs or sneezes and can also be contracted by touching contaminated surfaces. Due to its ease of transmission, it frequently spreads in schools, daycare facilities and nursing homes.
Symptoms of RSV
Symptoms of RSV usually begin to manifest within four to six days after exposure. The severity of symptoms can vary, influenced by factors such as age and pre-existing health conditions. Common signs include runny nose, persistent coughing, sneezing, fever, wheezing, loss of appetite, and in severe cases, difficulty breathing.
Older individuals with chronic lung or heart conditions may experience more significant respiratory issues, such as pneumonia, which may necessitate hospitalization.
High-Risk Groups
■ Infants, particularly those born prematurely or with health complications.
■ Children under the age of 2 who have chronic lung or congenital heart disease.
■ Adults over 65, especially those with weakened immune systems or chronic respiratory conditions like COPD or asthma.
■ Immunocompromised individuals of all ages.
Preventive Measures and Vaccines
For many years, RSV prevention was limited, as no specific vaccines existed. However, recent medical advancements have led to vaccines and treatments that provide greater protection for high-risk groups.
Vaccination for Older Adults
In 2023, the FDA approved a vaccine known as Arexvy, designed for adults aged 60 and over. This vaccine aims to reduce the risk of severe illness caused by RSV, particularly for seniors who are at an elevated risk for hospitalization. The vaccine is administered in a single dose to help protect against serious respiratory complications — ideally, before RSV season begins.
RSV, though common, can lead to serious health risks for certain individuals. Recognizing its symptoms and the current availability of new vaccines offer hope in reducing severe cases, particularly among those most at risk. With proper preventive measures, we can significantly reduce both the spread and the impact of RSV.
CARE PLUS by OHANA PACIFIC MEDICAL LLC
1150 S. King St. #1007, Honolulu, HI 96814
808-930-9858 | info@micareplus.org
micareplus.org
Leave a Reply